{"id":249693,"date":"2023-12-22T00:00:00","date_gmt":"2023-12-22T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptoop0006-2023-biopharma-dry-and-wet-age-related-macular-degeneration\/"},"modified":"2026-04-27T11:17:27","modified_gmt":"2026-04-27T11:17:27","slug":"sptoop0006-2023-biopharma-dry-and-wet-age-related-macular-degeneration-special-topics-special-topics-gene-therapies-in","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptoop0006-2023-biopharma-dry-and-wet-age-related-macular-degeneration-special-topics-special-topics-gene-therapies-in\/","title":{"rendered":"Dry and Wet Age-Related Macular Degeneration &#8211; Special Topics &#8211; Special Topics: Gene Therapies in Ophthalmology (US)"},"content":{"rendered":"<p>The wet age-related macular degeneration (<abbr title=\"age-related macular degeneration\">AMD<\/abbr>) market in the United States is replete with intravitreal (<abbr title=\"intravitreal\">IVT<\/abbr>) therapies\u2014including Regeneron\u2019s Eylea, Roche \/ Genentech\u2019s Lucentis and Vabysmo, Biogen\u2019s Byooviz, Coherus\u2019s Cimerli, and Novartis\u2019s Beovu. Although <abbr title=\"intravitreal\">IVT<\/abbr> agents drive favorable outcomes for most patients, they require chronic injections that limit persistency and compliance and prevent long-term achievement of an optimal response. Gene therapy for wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> is on the horizon, bringing the potential to reduce <abbr title=\"intravitreal\">IVT<\/abbr> injections and improve outcomes for patients, although questions remain about the profiles of the most eligible candidates for these innovative therapeutic options. The market for <abbr title=\"intravitreal\">IVT<\/abbr> therapies to treat advanced dry <abbr title=\"age-related macular degeneration\">AMD<\/abbr> with geographic atrophy (<abbr title=\"geographic atrophy\">GA<\/abbr>) is far less developed, but gene therapy is also advancing in the pipeline. This report addresses key questions regarding ophthalmologists\u2019 willingness to prescribe emerging gene therapies in both forms of <abbr title=\"age-related macular degeneration\">AMD<\/abbr> and key drivers of their prescribing, their preferences regarding differentiating clinical attributes, and through conjoint analysis, the clinical attributes they prioritize when selecting optimal wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> gene therapy candidates.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What percentage of wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> or <abbr title=\"geographic atrophy\">GA<\/abbr> patients are treated with key <abbr title=\"intravitreal\">IVT<\/abbr> agents? What percentage show a meaningful positive response?<\/li>\n<li>On average, how many injections per year do patients receive with key current therapies? What percentage of patients want a lower injection frequency than they can currently achieve?<\/li>\n<li>Where do ophthalmologists rank <abbr title=\"intravitreal\">IVT<\/abbr>, subretinal, and suprachoroidal gene therapy delivery among potential achievements for future wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> therapies?<\/li>\n<li>Based on available information, how willing are U.S. ophthalmologists to prescribe emerging gene therapies to their wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> or <abbr title=\"geographic atrophy\">GA<\/abbr> patients? What percentage of patients are candidates for these treatments?<\/li>\n<li>Which wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> patients are most likely to receive a gene therapy? How does a patient\u2019s status on their current <abbr title=\"intravitreal\">IVT<\/abbr> treatment\u2014including visual acuity, anatomical response, injection frequency, adverse events, eye treatment status, and age\u2014influence their likelihood to be prescribed a gene therapy?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<p><strong>Geography:<\/strong> United States<\/p>\n<p><strong>Primary Research: <\/strong>Survey of 101 U.S. ophthalmologists \/ retinal specialists in October 2023<\/p>\n<p><strong>Key agents covered:<\/strong> ABBV-RGX-314, ixo-vec (ADVM-022), 4D-150, JNJ-1887 (HMR59)<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Clarivate\u2019s Special Topics reports assess key trends in dynamic disease areas. This report on gene therapies in ophthalmology will help drug marketers and developers gain needed insight into treatment dynamics for <abbr title=\"intravitreal\">IVT<\/abbr> options in wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> and <abbr title=\"geographic atrophy\">GA<\/abbr>, <abbr title=\"healthcare provider\">HCP<\/abbr>s\u2019 desired achievements for emerging therapies, and physicians\u2019 willingness to prescribe key emerging gene therapies; it also provides a conjoint analysis of clinical attributes that render a wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> patient to be an optimal candidate to receive a future gene therapy.<\/p>\n","protected":false},"template":"","class_list":["post-249693","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-age-related-macular-degeneration","biopharma-therapy-areas-ophthalmology","biopharma-product-special-topics-other","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249693\/revisions"}],"predecessor-version":[{"id":281213,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249693\/revisions\/281213"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}